NHI-2 is a selective inhibitor of Lactate Dehydrogenase A (LDHA) – IC50 in vitro = 14.7 µM (NADH), 10.5 µM (Pyruvate). NHI-2 has also shown cellular growth inhibitory effects against pancreatic cancer cells (PANC-1 cells IC50 = 22.2 µM normoxic and 4.0 µM hypoxic; LPC006 cells IC50 = 17.8 µM...
Know who made it. See the evidence. Buy through one marketplace.
NHI-2 is a selective inhibitor of Lactate Dehydrogenase A (LDHA) – IC50 in vitro = 14.7 µM (NADH), 10.5 µM (Pyruvate). NHI-2 has also shown cellular growth inhibitory effects against pancreatic cancer cells (PANC-1 cells IC50 = 22.2 µM normoxic and 4.0 µM hypoxic; LPC006 cells IC50 = 17.8 µM normoxic and 1.1 µM hypoxic) with increased efficacy in a cancer cells hypoxic environment. LDHA is a key enzyme involved in the Warburg effect and a cancer cells ability to survive in a hypoxic environment
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
LDHA identifies lactate dehydrogenase A in Homo sapiens (Human). This target record connects NCBI Gene 3939, UniProtKB P00338 and related ABMIUM catalogue products.
